Boston Scientific Corp. reported its financial results for the fourth quarter and full year of 2024, exceeding Wall Street estimates. The company achieved adjusted earnings per share (EPS) of $0.70 for the fourth quarter, surpassing the consensus estimate of $0.66. Net sales for the quarter reached $4.561 billion, beating the expected $4.424 billion. For the full year, Boston Scientific reported adjusted EPS of $2.51, up from $2.05 the previous year, with net sales totaling $16.747 billion. The company's growth was driven by a 28.8% increase in the cardiovascular segment and the successful launch of the FARAPULSE™ system. Looking ahead to 2025, Boston Scientific anticipates adjusted EPS to be between $2.80 and $2.87, with expected net sales growth of 12.5% to 14.5% on a reported basis. For the first quarter of 2025, the company expects adjusted EPS to range from $0.66 to $0.68 and net sales growth to be between 17% and 19%.